Castle Biosciences, Inc. (CSTL) News
Track canonical SquawkNews coverage tagged to CSTL, Castle Biosciences, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 10 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
CSTL posted a significant top-to-bottom-line beat in Q226 @ KEYB
CSTL posted a significant top-to-bottom-line beat in Q226 @ KEYB
EQUITY | Jul 31, 2026, 11:16 AM UTC
H
AXTI +20%, COHU +15.7%, FND +11.2%, MPWR +9.8%, RYAN +9.1%, AMZN +8.9%, SPXC +7.8%, CDNA +5.9%, CSTL +5.2%, MMSI +4.7%, SPSC +4.7, GDYN +4.1
AXTI +20%, COHU +15.7%, FND +11.2%, MPWR +9.8%, RYAN +9.1%, AMZN +8.9%, SPXC +7.8%, CDNA +5.9%, CSTL +5.2%, MMSI +4.7%, SPSC +4.7, GDYN +4.1%, PTCT +3.3% after results
EARNINGS | Jul 30, 2026, 08:34 PM UTC
H
COHU +16.2%, AXTI +13.8%, AMZN +8.7%, MPWR +8.5%, FND +6.7%, ILMN +5%, GDYN +4.8%, CSTL +4.6%, CDNA +4.6%, EXPO +3.7%, PTCT +3.3% after resu
COHU +16.2%, AXTI +13.8%, AMZN +8.7%, MPWR +8.5%, FND +6.7%, ILMN +5%, GDYN +4.8%, CSTL +4.6%, CDNA +4.6%, EXPO +3.7%, PTCT +3.3% after results
EARNINGS | Jul 30, 2026, 08:18 PM UTC
L
Castle Biosciences Raises FY2026 Sales Guidance from $345.000M-$355.000M to $365.000M-$375.000M vs $352.291M Est
Castle Biosciences (NASDAQ: CSTL ) raises FY2026 sales outlook from $345.000 million-$355.000 million to $365.000 million-$375.000 million vs $352.291 million estimate.
EARNINGS | Jul 30, 2026, 08:17 PM UTC
L
CSTL CSTL - Castle Biosciences Reports Second Quarter 2026 Results
CSTL CSTL - Castle Biosciences Reports Second Quarter 2026 Results
EARNINGS | Jul 30, 2026, 08:06 PM UTC
L
CSTL Castle Biosciences RESULTS: Q2, Q2 Operating Income $-3.07M, Q2 Net Income $-2.06M, Q2 REV $103.546M vs. EST $86.2M, Q2 operating expen
CSTL Castle Biosciences RESULTS: Q2, Q2 Operating Income $-3.07M, Q2 Net Income $-2.06M, Q2 REV $103.546M vs. EST $86.2M, Q2 operating expenses $106.616M, Q2 pretax profit $-1.69M
EARNINGS | Jul 30, 2026, 08:05 PM UTC
L
CSTL Castle Biosciences announces New York State department of health approval of its advancead-tx™ test
CSTL Castle Biosciences announces New York State department of health approval of its advancead-tx™ test
EQUITY | Jul 14, 2026, 08:30 PM UTC
M
CSTL Outperforms MIA
CSTL's DecisionDx-Melanoma's i31-SLNB outperforms MIA Nomogram in identifying patients who may safely forgo sentinel lymph node biopsy
EQUITY | Jun 25, 2026, 08:31 PM UTC
M
TNXP: Raymond James Initiates
Raymond James analyst initiates coverage on Tonix Pharmaceuticals with a Strong Buy rating and a price target of $26
EQUITY | Jun 25, 2026, 12:44 PM UTC
M
CSTL: Roth Initiates Buy
Roth Capital initiates coverage on Castle Biosciences with a Buy rating and a price target of $40
EQUITY | Jun 25, 2026, 10:39 AM UTC